MedTrace Logo

Pilot Study: Gene Expression Profiling of Immune Response to HBV Vaccination in Healthy Volunteers

NCT02055365 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2018-05-07

Study results available
· View outcomes & findings →

Summary

Vaccines have been responsible for preventing millions of deaths and extending the average human lifespan. Effective vaccines stimulate the cells of the immune system to activate genes and associated functions that bring about protective immunity.This study aims to define cellular functions and genes important for the hepatitis B (HBV) vaccine immune response in healthy individuals. The investigators hypothesize that many genes associated with innate and adaptive immune functions are important for an effective HBV vaccine response.

Conditions

Interventions

BIOLOGICAL

Hepatitis B Vaccine (Recombinant)

All subjects will receive the standard 3-dose course of Recombivax HB (Merck) - Hepatitis B Vaccine (Recombinant).

Sponsors & Collaborators

  • Rockefeller University

    lead OTHER

Principal Investigators

  • Brad Rosenberg, MD, PhD · The Rockefeller University

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-02-18
Primary Completion
2015-01-06
Completion
2015-01-06

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02055365 on ClinicalTrials.gov